IP Library › Granted Patent US 9,370,532
Granted Patent B2
US 9,370,532 · App. 14/485,301 · Granted Jun 21, 2016

Prebiotic formulations and methods of use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,370,532
App. No.
14/485,301
Granted
Jun 21, 2016
Kind
B2
Abstract

The invention provides methods and compositions for treating symptoms associated with lactose intolerance and for overall improvement in gastrointestinal health. Described herein are methods and compositions for improving overall gastrointestinal health or for decreasing symptoms of lactose intolerance by administering to subject in need thereof a prebiotic composition, optionally in combination with effective amount of a probiotic microbe or microbes.

Claims (19)

1. A method for preventing or reducing diarrhea associated with lactose intolerance, the method comprising orally administering to a mammal an effective amount of a composition comprising a mixture of galactooligosaccharides, wherein the GOS comprises 1-10% by weight pentasaccharides and at least 45% by weight trisaccharides.

2. The method of claim 1 , wherein the diarrhea is acute diarrhea.

3. The method of claim 1 , wherein the mammal is a human.

4. The method of claim 1 , wherein the composition is a mixture of galactooligosaccharides comprising disaccharides; trisaccharides; tetrasaccharides and pentasaccharide.

5. The method of claim 1 , wherein the composition is a mixture of galactooligosaccharides comprising disaccharides Gal-Gal, trisaccharides Gal-Gal-Glc, a tetrasaccharide Gal-Gal-Gal-Glc and a pentasaccharide Gal-Gal-Gal-Gal-Glc, where Gal represents a galactose residue and Glc represents a glucose residue.

6. The method of claim 1 , wherein the mixture of galactooligosaccharides comprises disaccharide Gal (α 1-6)-Gal; trisaccharides Gal (β 1-6)-Gal (β 1-4)-Glc; Gal (β 1-3)-Gal (β 1-4)-Glc; tetrasaccharide Gal (β 1-6)-Gal (β 1-6)-Gal (β 1-4)-Glc and pentasaccharide Gal (β 1-6)-Gal (β 1-6)-Gal (β 1-6)-Gal (β 1-4) Glc.

7. The method of claim 1 , wherein the effective amount of the composition comprises from about 1 mg to about 10 g of the galactooligosaccharides wherein the galactooligosaccharides comprise 40% or more of the composition.

8. The method of claim 1 , wherein the effective amount of the composition comprises from about 1 g to about 5 g of the galactooligosaccharides, wherein the galactooligosaccharides comprise 40% or more of the composition.

9. The method of claim 1 , wherein the effective amount of the composition comprises about 3 g of the galactooligosaccharides, wherein the galactooligosaccharides comprise 40% or more of the composition.

10. The method of claim 6 , wherein the effective amount of the composition comprises from about 1 mg to about 10 g of the galactooligosaccharides wherein the galactooligosaccharides comprise 40% or more of the composition.

11. The method of claim 6 , wherein the effective amount of the composition comprises from about 1 g to about 5 g of the galactooligosaccharides, wherein the galactooligosaccharides comprise 40% or more of the composition.

12. The method of claim 6 , wherein the effective amount of the composition comprises about 3 g of the galactooligosaccharides, wherein the galactooligosaccharides comprise 40% or more of the composition.

13. The method of claim 1 , wherein the effective amount of the composition is administered daily as a single dose.

14. The method of claim 1 , wherein the effective amount of the composition is administered in two separate doses at different times.

15. The method of claim 1 , wherein the effective amount of the composition comprises from about 1 g to about 20 g of the galactooligosaccharides wherein the galactooligosaccharides comprise 40% or more of the composition.

16. The method of claim 1 , wherein the effective amount of the composition comprises from about 10 g to about 20 g of the galactooligosaccharides wherein the galactooligosaccharides comprise 40% or more of the composition.

17. The method of claim 1 , wherein the effective amount of the composition comprises from about 15 g to about 20 g of the galactooligosaccharides wherein the galactooligosaccharides comprise 40% or more of the composition.

18. A method for the reduction in severity of diarrhea associated with lactose intolerance comprising orally administering to a mammal an effective amount of a galactooligosaccharide composition, wherein the GOS comprises 1-10% by weight pentasaccharides and at least 45% by weight trisaccharides.

19. The method of claim 18 , wherein the diarrhea is acute diarrhea.